Vaxart, Inc. (VXRT) Spending and interest coverage
- R&D / revenue · 12 months: Value 75.81%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 2.68%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 75.81% | Research and development expense / revenue. Period ending 2026-06-30. $184.26M ÷ $243.06M × 100 ≈ 75.81% |
| Stock-based compensation / revenue · 12 months | 2.68% | Share-based compensation / revenue. Period ending 2026-06-30. $6.51M ÷ $243.06M × 100 ≈ 2.68% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 184.26M USD | Research and Development Expense |
| Revenue | 243.06M USD | |
| Stock-based compensation | 6.51M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 39.61M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $184.26M | $243.06M | $6.51M | $39.61M | (m) | 75.81% | 2.68% | (m) | (m) |
| 2026-03-31 | $200.25M | $255.61M | $7.34M | $38.18M | (m) | 78.34% | 2.87% | (m) | (m) |
| 2025-12-31 | $201.58M | $237.26M | $8.31M | $18.07M | (m) | 84.96% | 3.50% | (m) | (m) |
| 2025-09-30 | $179.08M | $148.20M | $8.95M | $-48.84M | (m) | 120.83% | 6.04% | (m) | (m) |
| 2025-06-30 | $118.20M | $80.72M | $9.41M | $-55.51M | (m) | 146.42% | 11.66% | (m) | (m) |
| 2025-03-31 | $85.94M | $47.40M | $9.84M | $-57.16M | (m) | 181.34% | 20.77% | (m) | (m) |
| 2024-12-31 | $74.21M | $28.70M | $11.50M | $-66.29M | (m) | 258.58% | 40.07% | (m) | (m) |
| 2024-09-30 | $66.26M | (m) | $12.86M | $-71.70M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $66.20M | (m) | $14.23M | $-75.05M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $67.53M | (m) | $15.60M | $-81.84M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $68.14M | (m) | $14.13M | $-83.35M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $73.90M | (m) | $13.81M | $-97.58M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $81.36M | (m) | $13.61M | $-109.19M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $82.47M | (m) | $13.10M | $-115.38M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $81.05M | (m) | $13.59M | $-114.59M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $76.13M | (m) | $13.11M | $-107.66M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $66.07M | (m) | $11.56M | $-95.49M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $56.88M | (m) | $10.75M | $-82.02M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $48.75M | (m) | $8.87M | $-72.75M | $0.00 | (m) | (m) | (m) | Reported |
| 2021-09-30 | $41.81M | (m) | $6.44M | $-61.90M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $34.02M | (m) | $5.26M | $-52.24M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $28.39M | (m) | $5.51M | $-44.99M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $19.86M | (m) | $4.36M | $-30.17M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $14.56M | (m) | $4.01M | $-22.43M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $13.66M | (m) | $3.24M | $-19.56M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $12.25M | (m) | $559.00K | $-16.03M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $14.54M | (m) | $627.00K | $-15.79M | $315.00K | (m) | (m) | -50.11× | Reported |
| 2019-09-30 | $15.72M | (m) | $642.00K | $-14.35M | $407.00K | (m) | (m) | -35.25× | Reported |
| 2019-06-30 | $16.39M | (m) | $679.00K | $-15.51M | $452.00K | (m) | (m) | -34.32× | Reported |
| 2019-03-31 | $17.70M | $8.06M | $617.00K | $-18.29M | $491.00K | 219.47% | 7.65% | -37.25× | Reported |
| 2018-12-31 | $17.27M | $4.16M | $539.00K | $-21.76M | $821.00K | 415.36% | 12.96% | -26.50× | Reported |
| 2018-09-30 | $15.30M | $5.09M | $687.00K | $-20.47M | (m) | 300.49% | 13.49% | (m) | (m) |
| 2018-06-30 | $13.72M | $4.91M | $1.00M | $-19.59M | (m) | 279.37% | 20.44% | (m) | (m) |
| 2018-03-31 | $12.41M | $4.40M | $1.39M | $-17.41M | (m) | 281.81% | 31.48% | (m) | (m) |
| 2017-12-31 | $15.80M | $7.80M | $1.80M | $-17.20M | (m) | 202.56% | 23.08% | (m) | (m) |
| 2017-09-30 | $23.50M | $8.90M | $2.00M | $-22.90M | (m) | 264.04% | 22.47% | (m) | (m) |
| 2017-06-30 | $28.30M | $8.90M | $1.90M | $-27.50M | (m) | 317.98% | 21.35% | (m) | (m) |
| 2017-03-31 | $30.50M | $9.30M | $1.80M | $-28.60M | (m) | 327.96% | 19.35% | (m) | (m) |
| 2016-12-31 | $32.30M | $9.80M | $1.70M | $-30.10M | (m) | 329.59% | 17.35% | (m) | (m) |
| 2016-09-30 | $28.40M | $7.70M | $1.80M | $-28.10M | (m) | 368.83% | 23.38% | (m) | (m) |
| 2016-06-30 | $26.30M | $9.30M | $2.00M | $-25.20M | (m) | 282.80% | 21.51% | (m) | (m) |
| 2016-03-31 | $25.70M | $12.90M | $2.10M | $-38.50M | (m) | 199.22% | 16.28% | (m) | (m) |
| 2015-12-31 | $21.90M | $13.40M | $2.30M | $-32.20M | (m) | 163.43% | 17.16% | (m) | (m) |
| 2015-09-30 | $20.40M | $25.60M | $2.30M | $-19.20M | (m) | 79.69% | 8.98% | (m) | (m) |
| 2015-06-30 | $19.80M | $24.60M | $2.10M | $-19.50M | (m) | 80.49% | 8.54% | (m) | (m) |
| 2015-03-31 | $20.70M | $28.90M | $1.90M | $-10.00M | (m) | 71.63% | 6.57% | (m) | (m) |
| 2014-12-31 | $20.10M | $52.50M | $1.80M | $-7.90M | (m) | 38.29% | 3.43% | (m) | (m) |
| 2014-09-30 | $19.40M | $57.10M | $1.80M | $-14.40M | (m) | 33.98% | 3.15% | (m) | (m) |
| 2014-06-30 | $17.50M | $68.70M | $1.70M | $-11.50M | (m) | 25.47% | 2.47% | (m) | (m) |
| 2014-03-31 | $16.90M | $69.60M | $1.50M | $-7.40M | (m) | 24.28% | 2.16% | (m) | (m) |
| 2013-12-31 | $17.20M | $52.60M | $1.60M | $-10.60M | (m) | 32.70% | 3.04% | (m) | (m) |
| 2013-09-30 | $17.60M | $44.40M | $2.70M | $-18.40M | (m) | 39.64% | 6.08% | (m) | (m) |
| 2013-06-30 | $19.20M | $33.60M | $2.60M | $-22.10M | (m) | 57.14% | 7.74% | (m) | (m) |
| 2013-03-31 | $13.46M | $24.14M | (m) | $-14.79M | (m) | 55.73% | (m) | (m) | (m) |
| 2012-12-31 | $10.04M | $12.28M | (m) | $-16.98M | (m) | 81.74% | (m) | (m) | (m) |
| 2012-09-30 | $7.58M | $2.73M | $2.99M | $-11.16M | (m) | 277.62% | 109.56% | (m) | (m) |
| 2012-06-30 | $8.82M | $3.18M | $2.58M | $-11.98M | (m) | 277.07% | 81.19% | (m) | (m) |
| 2012-03-31 | $13.95M | $6.30M | $2.57M | $-13.80M | (m) | 221.50% | 40.84% | (m) | (m) |
| 2011-12-31 | $17.77M | $14.84M | $2.17M | $-9.76M | (m) | 119.73% | 14.60% | (m) | (m) |
| 2011-09-24 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | $33.50M | $12.50M | $600.00K | $-30.50M | (m) | 268.00% | 4.80% | (m) | (m) |
| 2011-06-25 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-26 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-25 | $26.08M | $35.01M | $3.92M | $-1.20M | $210.00K | 74.50% | 11.21% | -5.70× | Reported |
| 2010-09-25 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-26 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-26 | $16.49M | $10.49M | $2.46M | $-17.98M | $1.07M | 157.21% | 23.48% | -16.78× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |